HUP0103836A2 - Pyrrolo[2,3d]pyrimidine compositions and their use - Google Patents

Pyrrolo[2,3d]pyrimidine compositions and their use

Info

Publication number
HUP0103836A2
HUP0103836A2 HU0103836A HUP0103836A HUP0103836A2 HU P0103836 A2 HUP0103836 A2 HU P0103836A2 HU 0103836 A HU0103836 A HU 0103836A HU P0103836 A HUP0103836 A HU P0103836A HU P0103836 A2 HUP0103836 A2 HU P0103836A2
Authority
HU
Hungary
Prior art keywords
pyrrolo
pyrimidine compositions
pyrimidine
compositions
Prior art date
Application number
HU0103836A
Other languages
Hungarian (hu)
Inventor
Arlindo L. Castelhano
Bryan Mckibben
David J. Witter
Original Assignee
Osi Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.
Publication of HUP0103836A2 publication Critical patent/HUP0103836A2/en
Publication of HUP0103836A3 publication Critical patent/HUP0103836A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0103836A 1998-06-02 1999-06-01 Pyrrolo[2,3d]pyrimidine compositions and their use HUP0103836A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8770298P 1998-06-02 1998-06-02
US12321699P 1999-03-08 1999-03-08
US12652799P 1999-03-26 1999-03-26
PCT/US1999/012135 WO1999062518A1 (en) 1998-06-02 1999-06-01 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE

Publications (2)

Publication Number Publication Date
HUP0103836A2 true HUP0103836A2 (en) 2002-02-28
HUP0103836A3 HUP0103836A3 (en) 2003-05-28

Family

ID=27375739

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103836A HUP0103836A3 (en) 1998-06-02 1999-06-01 Pyrrolo[2,3d]pyrimidine compositions and their use

Country Status (25)

Country Link
US (3) US6800633B2 (en)
EP (2) EP2011499A3 (en)
JP (1) JP4611524B2 (en)
KR (1) KR100722194B1 (en)
CN (1) CN100528874C (en)
AP (1) AP1411A (en)
AR (1) AR020590A1 (en)
AU (1) AU763658B2 (en)
BR (1) BR9911612A (en)
CA (1) CA2334200C (en)
CZ (1) CZ302486B6 (en)
DZ (1) DZ2805A1 (en)
EA (1) EA003604B1 (en)
HU (1) HUP0103836A3 (en)
ID (1) ID27600A (en)
IL (1) IL139787A0 (en)
MX (1) MXPA00011889A (en)
NO (1) NO325233B1 (en)
NZ (1) NZ508314A (en)
OA (1) OA12147A (en)
PL (1) PL204628B1 (en)
TR (1) TR200003513T2 (en)
TW (1) TWI242435B (en)
WO (1) WO1999062518A1 (en)
YU (1) YU76100A (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
DE69638122D1 (en) * 1996-09-04 2010-03-18 Intertrust Tech Corp Reliable infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, trade-timing and automation, distributed processing and rights management
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
KR100722194B1 (en) 1998-06-02 2007-05-29 오에스아이 파마슈티컬스, 인코포레이티드 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2001039777A1 (en) * 1999-12-02 2001-06-07 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
DE60107835T2 (en) 2000-04-26 2005-12-22 Eisai Co., Ltd. MEDICAL COMPOSITIONS FOR PROMOTING THE ACTIVATION OF THE DIGES
EP1301490A2 (en) 2000-07-18 2003-04-16 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
CN1926132B (en) * 2000-09-15 2010-12-29 沃泰克斯药物股份有限公司 Pyrazole compounds useful as protein kinase inhibitors
PE20020451A1 (en) 2000-09-15 2002-06-06 Vertex Pharma USEFUL PYRAZOLE COMPOUNDS AS KINASE PROTEIN INHIBITORS
SI1318997T1 (en) * 2000-09-15 2006-12-31 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
UA74228C2 (en) * 2000-12-01 2005-11-15 Осі Фармасьютікалз, Інк. DERIVATIVES OF PYRROLO[2,3-d]PYRIMIDINE, SPECIFIC TO ADENOSINE A<sub>1, A</sub><sub>2А AND A</sub><sub>3 RECEPTORS, A METHOD FOR PRODUCING THEREOF AND A PHARMACEUTICAL COMPOSITION
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP4579497B2 (en) * 2000-12-01 2010-11-10 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Compounds specific for adenosine A1, A2A and A3 receptors and uses thereof
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
GB0100622D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
DE10148883A1 (en) * 2001-10-04 2003-04-10 Merck Patent Gmbh New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
EP1450811B1 (en) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
EP1467995B1 (en) * 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
WO2003053366A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
US20030229067A1 (en) * 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
CA2479036A1 (en) 2002-03-13 2003-09-18 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
AR043880A1 (en) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh ACID MESILATE 4- (4.TRANS-HYDROXICICLOHEXIL) AMINO-2-PHENYL-7H-PIRROLO (2,3-D) PYRIMIDINE AND ITS POLYMORPHAS FORMS
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
UY29177A1 (en) 2004-10-25 2006-05-31 Astex Therapeutics Ltd SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
ES2533241T3 (en) 2005-11-03 2015-04-08 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP1968603A4 (en) * 2006-01-03 2013-01-16 Algebra Inc Therapeutic amine-arylsulfonamide conjugate compounds
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
ES2400104T3 (en) 2007-07-31 2013-04-05 Vertex Pharmaceuticals Incorporated Process for preparation of 5-fluoro-1H-pyrazolo [3,4-b] pyridin-3-amine and derivatives thereof
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009153261A1 (en) * 2008-06-18 2009-12-23 Solvay Pharmaceuticals Gmbh HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
CA2730106A1 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
ES2432821T3 (en) * 2008-07-31 2013-12-05 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
RU2011112802A (en) 2008-09-03 2012-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) CO-CRYSTALS AND THEIR PHARMACEUTICAL COMPOSITIONS
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2445877B1 (en) * 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
EP2445346A4 (en) * 2009-06-24 2012-12-05 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
TWI466885B (en) 2009-07-31 2015-01-01 Japan Tobacco Inc Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof
JP5579864B2 (en) * 2009-11-12 2014-08-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト N-9-substituted purine compounds, compositions and methods of use
JP5572715B2 (en) * 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト N-7 substituted purines and pyrazolopyrimidine compounds, compositions and methods of use
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
AR091271A1 (en) * 2012-06-07 2015-01-21 Hoffmann La Roche PIRROLOPIRIMIDONA AND PIRROLOPIRIDONA, TANQUIRASA INHIBITORS
JP6360881B2 (en) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase
CN110128316B (en) * 2019-05-22 2021-08-31 北京大学深圳研究生院 Preparation method of 5-substituted beta-proline and derivatives thereof
WO2022109495A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of California Methods and compositions for linking rna stem loops
CN113105469B (en) * 2021-04-13 2022-04-22 中国科学院新疆理化技术研究所 Tricyclic furo [2,3-d ] pyrimidone compound and application thereof
CN116621843B (en) * 2022-06-13 2024-05-24 四川大学华西医院 DNA methyltransferase 1 inhibitor and preparation method and application thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en) * 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
US3910913A (en) 1969-11-04 1975-10-07 American Home Prod 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
DE3145287A1 (en) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo[2,3-d]pyrimidines, process for their preparation and their use as medicaments
US4473571A (en) * 1983-01-17 1984-09-25 Sterling Drug Inc. 8-Substituted-2-(4-pyridinyl)-9H-purin-6-amines and their cardiotonic use
IN157280B (en) 1983-07-15 1986-02-22 Hoechst India
GB8729994D0 (en) 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
IL89028A0 (en) 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
ATE140457T1 (en) * 1989-09-19 1996-08-15 Teijin Ltd PYRROLO(2,3-D>PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION AND MEDICINAL COMPOSITIONS CONTAINING SAME
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5208240A (en) 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5516894A (en) 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
SK119194A3 (en) * 1992-04-03 1995-05-10 Upjohn Co Fharmaceuticaly active bicyclic-heterocyclic amines
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP0674641B1 (en) * 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
HUT72677A (en) 1993-02-26 1996-05-28 Merrell Dow Pharma Xanthine derivatives as adenosine a1 receptor antagonists
WO1994024136A1 (en) 1993-04-08 1994-10-27 The Trustees Of Columbia University In The City Of New York Method for the synthesis of 4- and/or 5-(di)substituted 2-aminoimidazoles from 2-aminoimidazoles and aldehydes
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1995018617A1 (en) 1994-01-10 1995-07-13 Teva Pharmaceutical Industries Ltd. 1-aminoindan derivatives and compositions thereof
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
HU220423B (en) 1994-01-26 2002-01-28 Novartis Ag. Modified oligonucleotides
US5646156A (en) 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
DE59500788D1 (en) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative activity
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
AU694801B2 (en) * 1994-09-29 1998-07-30 Novartis Ag Pyrrolo(2,3-d)pyrimidines and their use
WO1996019478A1 (en) 1994-12-19 1996-06-27 Novartis Ag 6'-substituted carbocyclic nucleosides
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5646130A (en) 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
IT1277392B1 (en) 1995-07-28 1997-11-10 Schering Plough S P A HEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C] PYRIMIDINE WITH ANTAGONIST ACTIVITY FOR THE A2A RECEPTOR OF ADENOSINE
US5780450A (en) 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
JPH09291089A (en) 1996-04-26 1997-11-11 Yamanouchi Pharmaceut Co Ltd New 5-thiazolyluracil derivative or its salt
JP3531169B2 (en) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 Fused heterocyclic compounds and their pharmaceutical uses
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US5780481A (en) 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
JP2000516961A (en) 1996-08-30 2000-12-19 イーライ・リリー・アンド・カンパニー Nonclassical pyrrolo [2,3-D] pyrimidine antifolates
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
AU7890598A (en) * 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
FR2763334A1 (en) 1997-05-13 1998-11-20 Lipha Piperazino alkyl anthranilic acid amide
JP2002505687A (en) * 1997-06-18 2002-02-19 ディスカバリー セラピューティクス，インコーポレイテッド Compositions and methods for preventing restenosis after a revascularization procedure
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6151484A (en) 1997-08-08 2000-11-21 Ericsson Inc. Communications apparatus and methods for adaptive signal processing based on mobility characteristics
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
KR100722194B1 (en) 1998-06-02 2007-05-29 오에스아이 파마슈티컬스, 인코포레이티드 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
US6878716B1 (en) * 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6528516B1 (en) 1998-07-16 2003-03-04 Trustees Of The University Of Pennsylvania, The Center For Technology Transfer Methods for reducing intraocular pressure using A3 adenosine receptor antagonists
US6463687B1 (en) * 1998-09-25 2002-10-15 Edward J. Dorstewitz Collapsible safety sign
US6158306A (en) 1998-10-06 2000-12-12 Gasparre; Pasquale Jar holder
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2001039777A1 (en) 1999-12-02 2001-06-07 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6628342B2 (en) 2000-01-05 2003-09-30 Matsushita Electric Industrial Co., Ltd. Video signal processing apparatus
JP3317948B2 (en) 2000-01-20 2002-08-26 エヌイーシーマイクロシステム株式会社 Layout design method of semiconductor integrated circuit and semiconductor integrated circuit
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP4579497B2 (en) 2000-12-01 2010-11-10 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Compounds specific for adenosine A1, A2A and A3 receptors and uses thereof
EP1450811B1 (en) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
WO2003053366A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
EP1467995B1 (en) 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
CA2516250A1 (en) 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
JP6297783B2 (en) 2013-03-08 2018-03-20 住友電気工業株式会社 Silicon carbide semiconductor device and manufacturing method thereof
CN103309150B (en) 2013-06-26 2015-06-17 上海华力微电子有限公司 Processing method for layout data
KR102109129B1 (en) 2013-07-02 2020-05-08 삼성전자주식회사 Reflective photomask blank and reflective photomask
JP6502627B2 (en) 2014-07-29 2019-04-17 太陽誘電株式会社 Coil parts and electronic devices
CN106531794B (en) 2015-09-15 2021-02-09 联华电子股份有限公司 High voltage metal oxide semiconductor transistor element and manufacturing method thereof

Also Published As

Publication number Publication date
EA200001245A1 (en) 2001-08-27
DZ2805A1 (en) 2005-01-30
AR020590A1 (en) 2002-05-22
US20050043332A1 (en) 2005-02-24
OA12147A (en) 2006-05-05
IL139787A0 (en) 2002-02-10
AU4226599A (en) 1999-12-20
NO20006090L (en) 2001-01-31
HUP0103836A3 (en) 2003-05-28
EP1082120A1 (en) 2001-03-14
TWI242435B (en) 2005-11-01
WO1999062518A1 (en) 1999-12-09
CZ302486B6 (en) 2011-06-15
AP1411A (en) 2005-05-10
US7429574B2 (en) 2008-09-30
CA2334200C (en) 2011-01-25
TR200003513T2 (en) 2001-06-21
PL204628B1 (en) 2010-01-29
MXPA00011889A (en) 2003-04-25
NZ508314A (en) 2004-03-26
NO325233B1 (en) 2008-03-03
PL347020A1 (en) 2002-03-11
JP2002516861A (en) 2002-06-11
YU76100A (en) 2003-12-31
KR20010083042A (en) 2001-08-31
CA2334200A1 (en) 1999-12-09
CN100528874C (en) 2009-08-19
AU763658B2 (en) 2003-07-31
EP2011499A2 (en) 2009-01-07
BR9911612A (en) 2001-02-06
US20090082369A1 (en) 2009-03-26
KR100722194B1 (en) 2007-05-29
AP2000002015A0 (en) 2000-12-31
JP4611524B2 (en) 2011-01-12
US6800633B2 (en) 2004-10-05
ID27600A (en) 2001-04-12
EA003604B1 (en) 2003-06-26
CZ20004443A3 (en) 2002-03-13
US20020028782A1 (en) 2002-03-07
CN1311680A (en) 2001-09-05
NO20006090D0 (en) 2000-11-30
EP2011499A3 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
PL347020A1 (en) Pyrrolo[2,3d]pyrimidine compositions and their use
HUP0103472A3 (en) Pyrrolo[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same
HK1036801A1 (en) Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of
HK1078574A1 (en) Pyrazolo [4,3-D] pyrimidine derivatives
HUP0203503A3 (en) Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
IL125358A0 (en) 5H-thiazolo [3,2-a] pyrimidine derivatives
EP0923287A4 (en) Nonclassical pyrrolo 2,3-d]pyrimidine antifolates
HUP0103921A3 (en) [1,2,4]triazolo[1,5-c]pyrimidine derivatives and pharmaceutical compositions thereof
ZA985121B (en) 3-Substituted 3,4-dihyrothieno(2,3-d)pyrimidine derivatives their preparation and use.
HK1034722A1 (en) Antipicornaviral compounds, their preparation and use
PL353366A1 (en) Pyrazolo[4,3-d]pyrimidines
HUP0102981A3 (en) Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
HUP0100140A3 (en) Synergetic fungicidal combination comprising thieno[2,3-d]pyrimidin-4-one derivative and its use
HUP0104350A3 (en) Synergetic fungicidal composition comprising thieno[2,3-d]pyrimidin-4-one and its use
ZA987114B (en) 3-substituted 3,4,5,7-tetrahydropyrrolol[3&#39;,4&#39;:4,5] thieno[2,3-D]pyrimidine derivatives, their preparation and use.
PL363077A1 (en) Use of pyrazolo[4,3-d]pyrimidines
IL150163A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND SOME NOVEL SUCH COMPOUNDS
ZA982912B (en) 6,7-disubstituted-4-aminopyrido [2,3-d] pyrimidine compounds
PL361890A1 (en) Use of pyrazolo[4,3-d]pyrimidines
PL336265A1 (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
EP0904271A4 (en) 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES
IL155379A0 (en) SUBSTITUTED 3,4-DIHYDRO-PYRIMIDO[1,2-a] PYRIMIDINES AND 3,4-DIHYDROPYRAZINO [1,2-a] PYRIMIDINES
HUP0104267A3 (en) 1,4-diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiane and 1,4-diaryl-2-fluoro-2-butene compounds
TW343509U (en) Multi-purpose cup

Legal Events

Date Code Title Description
NF4A Restoration of patent protection
FD9A Lapse of provisional protection due to non-payment of fees